Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren's ...

Ianalumab has the potential to become the first and only targeted treatment approved for patients with Sjögren’s disease Ianalumab was well tolerated and demonstrated a favorable safety profile in ...

Vitamin D is sometimes nicknamed the “sunshine vitamin” because your skin makes it when you’re out in the sun. You can also ...